Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Jasper Therapeutics Inc JSPR

Healthcare Biotechnology
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:JSPR)

Jasper Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire November 13, 2024

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2024

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

GlobeNewswire October 24, 2024

Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria

GlobeNewswire October 23, 2024

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

GlobeNewswire October 14, 2024

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

GlobeNewswire September 10, 2024

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

GlobeNewswire September 4, 2024

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire August 13, 2024

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

GlobeNewswire June 19, 2024
View More News ››

Opinion & Analysis (NDAQ:JSPR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:JSPR)

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Stu

JUST IN: $JSPR Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria14 of 15...
whytestocks - October 14, 2024

Jasper Therapeutics Presents Data from Preclinical Briquilim

NEWS: $JSPR Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid CongressREDWOOD CITY, Calif...
whytestocks - June 14, 2024

Jasper Therapeutics to Present at the Oppenheimer 34th Annua

JUST IN: $JSPR Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference | BenzingaREDWOOD CITY, Calif., Feb...
whytestocks - February 7, 2024

Jasper Therapeutics to Present at the Oppenheimer 34th Annua

Just In: $JSPR Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare ConferenceREDWOOD CITY, Calif., Feb. 07, 2024...
whytestocks - February 7, 2024

Jasper Therapeutics Announces Pricing of $50 Million Underwr

News; $JSPR Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common StockREDWOOD CITY, Calif., Feb. 06...
whytestocks - February 6, 2024

When (JSPR) Moves Investors should Listen

Breaking News: $JSPR When (JSPR) Moves Investors should Listen2024-02-05 01:50:00 ET Stock Traders Daily has produced this trading...
whytestocks - February 5, 2024
View more Bullboard ››

Equity Metals Corp

Equity Metals Corp

Equity Metals Corporation is engaged in the acquisition, exploration and development of mineral and diamond properties in ...
View More »